Changes in serum HSP27 levels in patients with multiple myeloma and correlation analysis with diagnosis, treatment, and prognosis
10.3760/cma.j.cn114452-20250122-00042
- VernacularTitle:多发性骨髓瘤患者血清HSP27的水平变化及与诊疗预后的相关性分析
- Author:
Yalan ZHANG
1
;
Ping LIN
;
Xueya ZHANG
Author Information
1. 福建医科大学附属第二医院临床医学检验中心，泉州 362000
- Publication Type:Journal Article
- Keywords:
Multiple myeloma;
Heat shock protein 27;
Diagnosis;
Prognosis
- From:
Chinese Journal of Laboratory Medicine
2025;48(10):1331-1336
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the levels of serum heat shock protein 27 (HSP27) in patients with multiple myeloma (MM) and its relationship with disease diagnosis, treatment, and prognosis.Method:Retrospective cohort study. We select 85 newly diagnosed MM patients from the Second Affiliated Hospital of Fujian Medical University from December 1, 2021 to June 30, 2023, including 43 males and 42 females, aged 60 (48, 81) years. Their serum HSP27 levels were measured at the time of initial diagnosis, and 100 healthy individuals who underwent physical examinations during the same period were recruited as controls. The correlation between serum HSP27 levels in MM patients and common clinical indicators such as gender, age, hemoglobin (Hb), serum creatinine (Cr), calcium (Ca), lactate dehydrogenase (LDH), β2-microglobulin levels (β2-MG), and bone marrow plasma cell ratio were analyzed; grouping 85 MM patients according to disease types and stages, and the differences in HSP27 levels before and after treatment in different MM classifications, stages, and treatments were compared; using receiver operating characteristic (ROC) curves to obtain the predictive value of initial HSP27 levels for remission in MM patients after standardized treatment, and calculating the optimal critical value. MM patients were divided into a high HSP27 group of 37 cases and a low HSP27 group of 48 cases based on the cutoff value, and Kaplan-Meier was used to compare the survival differences between the two groups.Result:The serum HSP27 levels in newly diagnosed MM patients were higher than those in healthy individuals [(281.33±27.69) pg/ml, (52.11±8.12) pg/ml, t=73.7, P0.001]. There was no correlation between HSP27 levels and patients' MM classification, gender, age, Hb serum Cr, Ca, LDH, and the proportion of bone marrow plasma cells, but positively correlated with β2-MG levels ( r=0.703, P0.05). There are significant differences in HSP27 levels at different stages of MM and before and after treatment; ROC curve results showed that serum HSP27 levels have certain predictive value for whether MM patients can achieve remission after treatment: sensitivity of 75.0%, specificity of 63.8%, and area under the curve of 0.720; the optimal cut-off value is 281.19 pg/ml. The survival time of the low HSP27 level group is longer than that of the high level group. Conclusion:Serum HSP27 is highly expressed in MM, and is correlated with the disease condition, treatment, and prognosis of MM.
